A path to the future in scleroderma
Role of PDGF in fibrotic diseases and systemic sclerosis
Pro- and anti-fibrotic effects of TGF-β in scleroderma
Connective tissue growth factor: growth factor, matricellular organizer, fibrotic biomarker or molecular target for anti-fibrotic therapy in SSc?
Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis
Criteria to select molecular targets for anti-fibrotic therapy
The microvascular endothelium in scleroderma
Macrovascular disease in systemic sclerosis: the tip of an iceberg?
Mechanisms of vascular damage in SSc—implications for vascular treatment strategies
Biomarkers of vascular disease in scleroderma
Endothelin—role in vascular disease
Endothelin and scleroderma lung disease
Expression and function of ETA and ETB receptors in SSc
Outcome measures in rheumatologic clinical trials and systemic sclerosis
A standardized core set for systemic sclerosis clinical trials. First step in development of combined response index
Screening for PAH in patients with systemic sclerosis: focus on Doppler echocardiography
Biomarkers in systemic sclerosis
Outcome measures in pulmonary arterial hypertension associated with systemic sclerosis
Right ventricular function in scleroderma-related pulmonary hypertension
Skin involvement in systemic sclerosis
Digital ulcers and outcomes assessment in scleroderma
Outcome measures in the lung
Outcome measures for heart involvement in systemic sclerosis
Renal manifestations of systemic sclerosis—clinical features and outcome assessment
Trial design: how must we move ahead?
High-resolution computed tomography and scleroderma lung disease
Histopathology and bronchoalveolar lavage
Pulmonary function tests
The 6-minute walk test in scleroderma—how measuring everything measures nothing